Leukocyte News and Research

RSS

Study explains why some cancer vaccines are not as effective as hoped

A research report published in the September 2012 issue of the Journal of Leukocyte Biology offers a possible explanation of why some cancer vaccines are not as effective as hoped, while at the same time identifies a new therapeutic strategy for treating autoimmune problems. In the report, scientists suggest that cancer, even in the very early stages, produces a negative immune response from dendritic cells, which prevent lymphocytes from working against the disease.

31 Aug 2012

Researchers discover new immune response mechanism during infection

Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered a new "first response" mechanism that the immune system uses to respond to infection. The findings challenge the current understanding of immunity and could lead to new strategies for boosting effectiveness of all vaccines. The study, conducted in mice, published online today in the journal Immunity.

31 Aug 2012

Sicor Biotech receives FDA approval for tbo-filgrastim to treat severe neutropenia

The U.S. Food and Drug Administration today approved Sicor Biotech's tbo-filgrastim to reduce the time certain patients receiving cancer chemotherapy experience severe neutropenia, a decrease in infection-fighting white blood cells called neutrophils.

30 Aug 2012

CNIO team generates transgenic mouse model for aplastic anaemia associated with short telomeres

Aplastic anaemia is characterised by a reduction in the number of the bone marrow cells that go on to form the different cell types present in blood (essentially red blood cells, white blood cells and platelets). In most cases, the causes of the disorder are hard to determine, but some patients have been found to have genetic alterations leading to a shortening of their telomeres (the end regions of chromosomes that protect and stabilise DNA).

30 Aug 2012

Vitamin to the rescue in fight with ‘superbugs’

High doses of vitamin B3 may help fight against so called “superbugs” such as methicillin-resistant Staphylococcus aureus, show study results.

29 Aug 2012

High doses of vitamin B3 stimulate CEBPE gene, enhance WBCs’ ability to combat staph infections

Cedars-Sinai researchers have found that a common vitamin may have the potential to provide a powerful weapon to fight certain "superbugs," antibiotic-resistant staph infections that health experts see as a threat to public health.

28 Aug 2012

Nicotinamide may combat antibiotic-resistance staph infections

A new study suggests that nicotinamide, more commonly known as vitamin B3, may be able to combat some of the antibiotic-resistance staph infections that are increasingly common around the world, have killed thousands and can pose a significant threat to public health.

28 Aug 2012

New blood test can predict which heart failure patients would benefit from ICDs

A novel blood test that predicts sudden death risk in heart failure patients is set to help physicians decide which patients would benefit from implantable cardioverter defibrillators (ICDs).

27 Aug 2012

The Wistar Institute, MSKCC partner to publish first annotated atlas of Epstein-Barr virus genome

Researchers from The Wistar Institute and Memorial Sloan-Kettering Cancer Center (MSKCC) have teamed to publish the first annotated atlas of the Epstein-Barr virus genome, creating the most comprehensive study of how the viral genome interacts with its human host during a latent infection. Epstein-Barr virus (EBV), which is thought to be responsible for one percent of all human cancers, establishes a latent infection in nearly 100 percent of infected adult humans.

24 Aug 2012

Injectable controlled-release capsules against gum disease

Scientists are trying to open a new front in the battle against gum disease, the leading cause of tooth loss in adults and sometimes termed the most serious oral health problem of the 21st century. They described another treatment approach for the condition in a report here today at the 244th National Meeting & Exposition of the American Chemical Society, the world's largest scientific society.

20 Aug 2012

Cedars-Sinai's ICT-107 doubles median survival of patients with malignant brain tumor

An experimental immune-based therapy more than doubled median survival of patients diagnosed with the most aggressive malignant brain tumor, Cedars-Sinai Medical Center researchers reported in Cancer Immunology, Immunotherapy, published online Aug. 3.

16 Aug 2012

Researchers identify key element in the development of Burkitt lymphoma

Burkitt lymphoma is a malignant, fast-growing tumor that originates from a subtype of white blood cells called B lymphocytes of the immune system and often affects internal organs and the central nervous system. Now Dr. Sandrine Sander and Professor Klaus Rajewsky of the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch have identified a key element that transforms the immune cells into malignant lymphoma cells.

14 Aug 2012

Targeting elevated HLX gene expression may treat acute myeloid leukemia

Scientists at Albert Einstein College of Medicine of Yeshiva University have made a discovery involving mice and humans that could mean that people with acute myeloid leukemia (AML), a rare and usually fatal cancer, are a step closer to new treatment options. Their study results were published online today in Cancer Cell.

14 Aug 2012

Scientists identify new genetic alterations underlying high-risk subtype of ALL

Scientists have identified new genetic alterations underlying a high-risk subtype of the most common childhood cancer that could be effectively targeted with existing leukemia therapies.

14 Aug 2012

Meritage commences OBS Phase 2 clinical trial for eosinophilic esophagitis

Meritage Pharma, Inc. announced that it has initiated a Phase 2 clinical trial to evaluate oral budesonide suspension (OBS) for the treatment of adolescents and young adults with eosinophilic esophagitis (EoE), an allergic inflammatory condition of the esophagus. EoE is a chronic disease characterized by symptoms related to esophageal dysfunction and eosinophil-predominant inflammation.

13 Aug 2012

Researchers uncover how pathological cells activate themselves in chronic lymphocytic leukaemia

Researchers in the group of Prof. Dr. Hassan Jumaa, Centre for Biological Signalling Studies (BIOSS) of the University of Freiburg, Department for Molecular Immunology, have identified a new mechanism that causes immune cells to convert into malignant cancer cells.

13 Aug 2012

FDA approved drug to treat Ph- acute lymphoblastic leukemia

The U.S. Food and Drug Administration today approved Marqibo (vincristine sulfate liposome injection) to treat adults with a rare type of leukemia called Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing form of blood and bone marrow cancer that is more commonly diagnosed in children than adults.

10 Aug 2012

Link between chronic exposure to staph bacteria and risk of lupus

Chronic exposure to even small amounts of staph bacteria could be a risk factor for the chronic inflammatory disease lupus, Mayo Clinic research shows. Staph, short for Staphylococcus aureus, is a germ commonly found on the skin or in the nose, sometimes causing infections.

9 Aug 2012

New method gives precise picture of how immune system works

Chronic infections are a large and growing problem throughout the developed world, and intensive research is being conducted in ways to combat the recalcitrant bacteria. When bacteria aggregate into so-called biofilm, they become resistant to antibiotics. Until now scientists have only been able to speculate about what happens when bacteria overpower the immune system during a chronic infection.

9 Aug 2012

WSU researchers to test novel hypothesis that cardiolipin deficiency leads to disruption of TCA cycle

Barth Syndrome (BTHS) is a rare and serious genetic disorder that primarily affects males and is passed from mother to son; women who are carriers do not show symptoms of the disorder. Fifty percent of children born to a mother who is a carrier will inherit the defective gene, and all daughters born to an affected man will be carriers. BTHS is caused by a mutation in the tafazzin gene that results in decreased production of cardiolipin, an essential lipid for energy metabolism.

8 Aug 2012

Leukocyte News and Research

Study explains why some cancer vaccines are not as effective as hoped

Researchers discover new immune response mechanism during infection

Sicor Biotech receives FDA approval for tbo-filgrastim to treat severe neutropenia

CNIO team generates transgenic mouse model for aplastic anaemia associated with short telomeres

Vitamin to the rescue in fight with ‘superbugs’

High doses of vitamin B3 stimulate CEBPE gene, enhance WBCs’ ability to combat staph infections

Nicotinamide may combat antibiotic-resistance staph infections

New blood test can predict which heart failure patients would benefit from ICDs

The Wistar Institute, MSKCC partner to publish first annotated atlas of Epstein-Barr virus genome

Injectable controlled-release capsules against gum disease

Cedars-Sinai's ICT-107 doubles median survival of patients with malignant brain tumor

Researchers identify key element in the development of Burkitt lymphoma

Targeting elevated HLX gene expression may treat acute myeloid leukemia

Scientists identify new genetic alterations underlying high-risk subtype of ALL

Meritage commences OBS Phase 2 clinical trial for eosinophilic esophagitis

Researchers uncover how pathological cells activate themselves in chronic lymphocytic leukaemia

FDA approved drug to treat Ph- acute lymphoblastic leukemia

Link between chronic exposure to staph bacteria and risk of lupus

New method gives precise picture of how immune system works

WSU researchers to test novel hypothesis that cardiolipin deficiency leads to disruption of TCA cycle

Immunology eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News